Annual report pursuant to Section 13 and 15(d)

SIGNIFICANT CONCENTRATIONS

v3.8.0.1
SIGNIFICANT CONCENTRATIONS
12 Months Ended
Dec. 31, 2017
SIGNIFICANT CONCENTRATIONS  
SIGNIFICANT CONCENTRATIONS

3. SIGNIFICANT CONCENTRATIONS

For the year ended December 31, 2017, BerGenBio and another unrelated third party accounted for 74% and 26% of our revenues, respectively. For the year ended December 31, 2016, BMS and BerGenBio accounted for 82% and 18% of our revenues, respectively. For the year ended December 31, 2015, BMS, Aclaris and another third party accounted for 60%,  28% and 12% of our revenues, respectively. As of December 31, 2017 and 2016, we had no accounts receivable.